Stockwinners Market Radar for November 22, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:24 EST Toast director Bennett sells 132,709 class A shares - In a regulatory filing, Toast director Richard Kent Bennett disclosed the sale of 132,709 class A common shares of the company on November 18 at a price of $18.27 per share.

19:14 EST Carvana CPO Gill acquires 133,000 class A shares - In a regulatory filing, Carvana chief product officer Daniel Gill disclosed the purchase of 133,000 class A shares of the company on November 21 at a price of $7.62 per share.

18:23 EST Helix Energy announces contract extension with Talos for Helix Producer I - Helix Energy Solutions Group, Inc. (HLX) announced that an affiliate of Talos Energy Inc. (TALO) has extended for one year the term of its contract with Helix for the Helix Producer I floating production vessel in the Gulf of Mexico. The one-year extension term is scheduled to conclude on June 1, 2024 with Talos having the option to extend the contract annually. Scotty Sparks, Helix's Executive Vice President and Chief Operating Officer, stated, "We are pleased to extend our contract on the Helix Producer I and look forward to continuing our long-term working relationship with Talos. The Helix Producer I is a unique vessel that has provided safe and reliable production processing for Talos, and this extension further demonstrates our ability to continue meeting our clients' needs. We continue to support the Energy Transition by offering clients the ability to maximize production from their existing wells."

18:00 EST UFP Technologies Chairman Bailly sells $1.2M in company shares - Chairman of UFP Technologies Jeffrey Bailly disclosed in a regulatory filing that he had sold 9,877 shares of company stock at $117.72 per share on November 21, for a total transaction amount of $1,162,708.

17:49 EST HP says FY23 free cash flow guidance includes $400M of restructuring charges - Sees FY23 free cash flow $3B-$3.5B. Guidance taken from Q4 earnings conference call.

17:20 EST U.K.'s CMA launches probe into cloud gaming, mobile browsers - The U.K.'s Competition and Markets Authority has launched a market investigation into cloud gaming and mobile browsers after receiving widespread support for its proposals first published in June. The CMA consulted on launching a market investigation alongside its Mobile Ecosystem Market Study report, which found that Apple (AAPL) and Google (GOOGL) have an effective duopoly on mobile ecosystems that allows them to exercise a stranglehold over operating systems, app stores and web browsers on mobile devices. Responses to the consultation, which have been published today, reveal substantial support for a fuller investigation into the way that Apple and Google dominate the mobile browser market and how Apple restricts cloud gaming through its App Store. Many of those came from browser vendors, web developers, and cloud gaming service providers who say that the status quo is harming their businesses, holding back innovation, and adding unnecessary costs.

17:16 EST Amedisys names Scott Ginn as acting COO - Amedisys names Scott Ginn, Executive Vice President and CFO, its Acting COO, effective immediately. Ginn has led financial teams at Amedisys since 2007, serving as Senior Vice President of Accounting and Controller and Chief Accounting Officer before being named CFO in 2017 and then being promoted to Executive Vice President in 2021.

16:59 EST MDU plans to make make capital investments totaling $3.5B over 2023-2027 - MDU Resources Group announced its plans to make capital investments totaling $3.5B over the five-year period from 2023 to 2027. "Our capital investment plan includes a number of key projects that are expected to provide organic growth across our businesses, with particular emphasis on upgrades and expansions to our electric transmission and distribution infrastructure and our natural gas transportation and distribution systems," said David L. Goodin, president and CEO of MDU Resources. "These capital investments encompass all our businesses while we continue to make progress toward our strategic initiatives of creating two pure-play public companies." MDU Resources plans to make substantial investments in its utility operations with a 27% increase in capital expenditures compared to the previous five years. The company anticipates its electric and natural gas utilities will grow rate base by approximately 6%-7% annually over the next five years on a compound basis. Customer growth is expected to continue at a rate of 1%-2% annually across the company's eight-state service territory. Total CapEx plan by year is $699M in FY22, $644M in FY23, $772M in FY24, $724M in FY25.

16:46 EST Farmers National Banc announces 21% boost in dividend to 17c per share - On November 22, the Board of Directors of the Farmers National Banc declared a quarterly cash dividend of 17c per share, representing a 21% increase over the same period last year. The common stock cash dividend will have a record date of December 9 and is payable to shareholders on December 30. "On behalf of Farmers' Board of Directors and Leadership Team, I am proud of the significant growth in our quarterly cash dividend payment," said Kevin J. Helmick, President and CEO of Farmers. "The 21% year-over-year increase in our quarterly cash dividend follows a 27% increase last year and marks the seventh consecutive year we have increased our annual dividend payment. We remain focused on profitably growing our bank, supporting our customers and communities, and creating value for our shareholders."

16:37 EST Blueprint Medicines submits sNDA to FDA for AYVAKIT - Blueprint Medicines announced the submission of a supplemental new drug application to the U.S. FDA for AYVAKIT for the treatment of adults with indolent systemic mastocytosis. AYVAKIT was designed to potently and selectively inhibit D816V mutant KIT, the underlying cause of SM in about 95% of cases. The submission includes data from the registrational PIONEER trial, the largest randomized, placebo-controlled clinical study ever conducted in indolent SM. The FDA has granted breakthrough therapy designation to AYVAKIT for the treatment of moderate to severe indolent SM

16:36 EST Nordstrom falls 5% to $21.52 after Q3 results, FY22 guidance

16:32 EST EchoStar, Maxar Technologies amend pact for Hughes JUPITER 3 production - EchoStar (SATS) announced an amended agreement with Maxar Technologies (MAXR) for production of the EchoStar XXIV satellite, also known as JUPITER 3. The satellite, designed for EchoStar's Hughes Network Systems division, is under production at Maxar's facility in Palo Alto, CA. The amended agreement compensates EchoStar for past production delays by providing relief on future payments and expands EchoStar's recourse in the event of any further delays. The satellite is currently planned to launch in the first half of 2023.

16:29 EST Autodesk falls 7% to $194.50 after Q3 results, FY23 guidance

16:20 EST HP Inc. increases quarterly dividend 5% to 26.25c per share - The HP board of directors has declared a quarterly cash dividend of 26.25c per share on the company's common stock, payable on January 4, 2023. This is an increase of 5% from the prior dividend.

16:17 EST SonocoThermoSafe and LATAM Cargo sign global master lease agreement - Sonoco ThermoSafe, a unit of Sonoco and one of the largest global providers of temperature assurance packaging, and LATAM Cargo, an international cargo airline with headquarters in Santiago de Chile, are pleased to announce a global lease agreement for the new Pegasus ULD temperature-controlled bulk shipping container. The agreement enables pharmaceutical freight forwarders access to Pegasus ULD containers directly from LATAM Cargo. Sonoco ThermoSafe's Pegasus ULD is the world's first FAA and EASA-approved passive bulk temperature-controlled ULD container for pharmaceutical use, which enables it to speed through international air freight handling and customs processes at the lowest possible cost. With a focus on sustainability, the Pegasus ULD is engineered with composite materials, offering a lighter solution that is also substantially more damage-resistant than traditional metal containers. Additionally, the Pegasus ULD contains a fully integrated, FAA-approved telemetry system providing real-time, cloud-based data on payload and ambient temperature and key environmental factors, precisely synchronized with GPS location.

16:17 EST Theravance Biopharma announces results of Dutch auction tender offer - Theravance Biopharma announced the final results of its Dutch auction tender offer to purchase up to $95M of its ordinary shares, par value $0.00001 per share, which expired at midnight, New York City time, at the end of the day on November 17. Based on the final count by Computershare Trust Company, N.A., the depositary for the Offer (the "Depositary"), a total of 115,967 Shares were properly tendered and not properly withdrawn. The company has accepted for purchase 115,967 Shares through the Offer at a price of $10.50 per Share, for an aggregate cost of approximately $1.2M, excluding fees and expenses relating to the Offer. The total of 115,967 Shares that the company has accepted for purchase represents approximately 0.2% of the total number of Shares outstanding as of November 21. As the company accepted for purchase all the Shares that were properly tendered and not properly withdrawn, there is no proration factor. The company intends to use the unused portion of the Offer to enlarge the company's previously announced, planned open market share repurchase plan, which the company expects to finalize and commence after the closing of the Offer.

16:10 EST Nordstrom says 'we are right-sizing our inventory levels' - "We are right-sizing our inventory levels and mix, and are on track to end 2022 in a healthy and current position," said Pete Nordstrom, president and chief brand officer of Nordstrom. "Customers continue to respond to newness and fashion in our offering, and we are focused on remaining agile to respond to their changing needs. This holiday season we are delivering a fresh, relevant assortment, which supports our goal of being the go-to destination for gifting, and preparing for the moments that matter most to customers."

16:08 EST Amneal launches second biosimilar with RELEUKO in U.S. - Amneal Pharmaceuticals announced the commercial launch of RELEUKO, a biosimilar referencing Neupogen. RELEUKO is used to treat neutropenia which is commonly experienced by patients undergoing chemotherapy. This product was developed in collaboration with Kashiv Biosciences, LLC located in Chicago, Illinois. "RELEUKO is our second U.S. biosimilar launch and represents the next step in building out our biosimilars business. This product is another important oncology therapeutic offering for providers and their patients as we look to make essential medicines more accessible for all," said Harsher Singh, SVP of Amneal Biosciences division. According to IQVIA, U.S. annual sales for filgrastim for the 12 months ended August 2022 were $390 million, of which $272 million represented biosimilar sales.

16:07 EST Aclaris names Dr. Neal Walker board chair, Doug Manion to transition to CEO role - Aclaris Therapeutics announced several key leadership changes. Effective January 1 co-founder and current chief executive officer, Dr. Neal Walker, will transition to the role of chair of the board of directors. Current chair, Christopher Molineaux, will remain on the board and transition to lead independent director. Dr. Doug Manion will transition from chief operating officer to the role of chief executive officer, while continuing to serve as president. Dr. Manion will also serve as a member of the Aclaris board of directors effective January 1, 2023. In addition, Aclaris is announcing the retirement of co-founder and chief financial officer Frank Ruffo effective December 31. Kevin Balthaser has been appointed chief financial officer, effective January 1. Aclaris is also announcing the appointment of Matthew Rothman, J.D. to the role of general counsel and corporate secretary, effective immediately. Mr. Rothman joined Aclaris in 2018 and has served in a number of roles of increasing responsibility within the legal department, most recently as vice president, legal and compliance.

16:06 EST Sterling announces transportation solutions $45M aviation award - Sterling Infrastructure announced that Ralph L. Wadsworth Construction Company, LLC was awarded the Phase 4 Terminal Redevelopment Program at the Salt Lake City International Airport. The design package consists of the gate expansion for the new North Concourse. The project scope involves airfield and civil work to connect adjacent taxiways and includes extensive electrical work to update lighting and signage. In addition, the demolition of taxiways, aprons, utilities and other related infrastructure will be completed to make way for the new installations in the design layout.

16:04 EST Autodesk announces $5B share repurchase program - In November, the Board of Directors authorized the repurchase of $5B of the company's common stock, in addition to the approximately 3.8M shares remaining, as of October 31, under previously announced share repurchase programs.

16:02 EST Opiant Pharmaceuticals completes rolling NDA submission for OPNT003 - Opiant Pharmaceuticals announced it has completed submission of its rolling new drug application, or NDA, to the FDA seeking approval for OPNT003, nasal nalmefene, for the treatment of opioid overdose.

16:01 EST Singularity Future Technology receives Nasdaq notice of non-compliance - Singularity Future Technology announced that on November 16, it received an additional staff determination notice from the Listing Qualifications Department of The Nasdaq Stock Market advising that it had not received the Company's Form 10-Q for the quarterly period ended September 30, 2022, which served as an additional basis for delisting the Company's securities and that Nasdaq Hearings Panel will consider the additional deficiency in rendering a determination regarding the company's continued listing on The Nasdaq Capital Market. The company has submitted to the Panel a plan to regain compliance with the continued listing requirements, including the filing of the Form 10-Q for the quarterly period ended September 30.

15:56 EST STB to hold in-person public hearing with Union Pacific over use of embargoes - The Surface Transportation Board announced that it will hold an in-person public hearing on December 13 and 14, 2022, with Union Pacific Railroad Company pertaining to the substantial increase in its use of embargoes as a method of reducing rail traffic congestion. UP's use of embargoes to control congestion has increased from a total of 5 in 2017 to more than 1,000 to date in 2022. The Board has received numerous reports that shippers are suffering supply chain problems as a result of the embargoes that are hampering their operations. The Board notes that UP carries nearly 27 percent of freight served by rail and nearly 11 percent of all long-distance freight volume. Therefore, disruptions in UP's service levels have a significant detrimental impact on the supply chain and the nation's economy. The Board has been closely monitoring UP's usage of embargoes and has noticed a disturbing upward trend in their usage in recent years. For these reasons, the Board is directing UP CEO Lance Fritz and other top executive-level officials of UP to appear at the hearing and expects to hear testimony on topics including, but not limited to, the railroad's decision-making process in determining whether to issue an embargo, data inputs, its consideration of shippers' operational needs, and explanations for the dramatic increase in embargoes since 2017. The Board also invites testimony from shippers and other stakeholders who can contribute to the Board's understanding of the cause and/or impact of the embargoes.

15:37 EST FDA approves CSL gene therapy to treat adults with Hemophilia B - The U.S. Food and Drug Administration approved Hemgenix, or etranacogene dezaparvovec, an adeno-associated virus vector-based gene therapy for the treatment of adults with Hemophilia B who currently use Factor IX prophylaxis therapy, or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes. Peter Marks, M.D., Ph.D., director of the FDA's Center for Biologics Evaluation and Research, said, "Today's approval provides a new treatment option for patients with Hemophilia B and represents important progress in the development of innovative therapies for those experiencing a high burden of disease associated with this form of hemophilia." The FDA granted approval of Hemgenix to CSL Behring. Reference Link

15:09 EST Mirati Therapeutics extends gain after volatility pause, now up 15%

15:06 EST Mirati Therapeutics up 9% after report of takeover interest

14:41 EST Manchester United jumps 13% in New York after report of owners exploring sale - Shares of the football club are up $1.63, or 13%, to $14.66 in New York trading on Tuesday afternoon following the report from Sky News' Mark Kleinman.

14:29 EST Manchester United trading halted, volatility trading pause

13:25 EST Tenaya treatment for ARVC due to PKP2 mutations granted orphan designation - Tenaya Therapeutics' treatment for arrhythmogenic right ventricular cardiomyopathy, or ARVC, due to PKP2 mutations was granted Orphan Designation by the FDA, according to a post to the agency's website. Reference Link

12:38 EST Meta communications director denies report that Zuckerberg will resign next year - Andy Stone, Meta's communications director, said on Twitter that a report claiming CEO Mark Zuckerberg is set to resign next year is false. Reference Link

12:03 EST Astrotech says BreathTest-100 can distinguish between infected, healthy samples - Astrotech Corporation announced that, based on analysis of data from testing of breath samples procured during library development, the BreathTest-1000 lung disease screening instrument can clearly distinguish between infected and healthy breath samples. The BreathTest-1000 is a breath analysis tool designed to screen for volatile organic compound metabolites found in a person's breath that could indicate they may have a bacterial or viral infection. To assist in the development of the BreathTest-1000, BreathTech has entered into development contracts with Cleveland Clinic, Mountain View Clinical Research, and Tools for AI, Inc. Cleveland Clinic is contracted to provide breath samples for several respiratory diseases including COVID-19, Mountain View is contracted to provide diseased and non-diseased breath samples, and Tools for AI is managing the artificial intelligence initiative.

12:00 EST Dycom falls -16.1% - Dycom is down -16.1%, or -$17.59 to $91.96.

12:00 EST Burlington Stores rises 14.5% - Burlington Stores is up 14.5%, or $22.79 to $180.43.

12:00 EST Abercrombie & Fitch rises 18.4% - Abercrombie & Fitch is up 18.4%, or $3.43 to $22.06.

10:59 EST Northwest Pipe to manufacture engineered steel pressure Texas pipeline project - Northwest Pipe was recently selected by S.J. Louis Construction and Alliance Regional Water Authority to produce engineered steel pressure pipe for Alliance Regional Water Authority Phase 1B-Segment D. Phase 1B is the second and largest phase of construction for this major water infrastructure project in Central Texas. When complete, Phase 1B will initially produce, treat, and deliver approximately 5,500 acre-feet of water per year, growing to 15,000 acre-feet per year through the future addition of wells and water treatment basins. "In this segment, we are manufacturing over 18 miles of engineered steel pipe for Alliance Water. We previously delivered over 5,100 tons to Alliance in 2021 for Segment A. We are pleased to again be working on this critical infrastructure project, which once completed, will serve over 225,000 residents in the area," said Scott Montross, President and Chief Executive Officer of Northwest Pipe Company. Montross continued, "As Texas continues to grow, we look forward to supporting their long-term water needs."

10:44 EST Dick's Sporting: Confidence is 'as high as it's been' - Sees "absolutely no signs" of any degradation entering Q4.

10:42 EST FIS up nearly 3% after Bloomberg report on job cutting plans - Shares of FIS are up $1.52, or about 2.5%, to $63.08 following Bloomberg's report.

10:23 EST AGBA Acquisition Ltd trading resumes

10:10 EST GRND Stock trading resumes

10:03 EST Sella Group launches biometric payment cards in collaboration with IDEMIA - IDEX Biometric announces that Sella Group in Italy has launched biometric payment cards in collaboration with IDEMIA, powered by IDEX Biometrics sensor solution. This launch follows the IDEX Biometrics recent announcement of a major UAE bank launching a full-scale biometric payment card program in the Middle East, indicating a significant market acceleration. The biometric payment card will initially be offered to selected target segments

10:00 EST Shift4 Payments falls -8.5% - Shift4 Payments is down -8.5%, or -$3.92 to $41.95.

10:00 EST Movado falls -12.5% - Movado is down -12.5%, or -$4.18 to $29.31.

10:00 EST Burlington Stores rises 16.8% - Burlington Stores is up 16.8%, or $26.41 to $184.05.

09:55 EST Dollar Tree sees mid-30% gross margin rates for Dollar Tree banner going forward - Comments taken from Q3 earnings conference call.

09:47 EST BeiGene to present final PFS results from ALPINE trial at ASH 2022 - Earlier, BeiGene (BGNE) announced that the results of the final progression free survival, or PFS, analysis of the ALPINE trial will be presented at a late-breaking oral presentation session at the 64th American Society of Hematology, or ASH, Annual Meeting in New Orleans. ALPINE is a global Phase 3 trial comparing Brukinsa with Imbruvida (JNJ) in patients with relapsed/refractory chronic lymphocytic leukemia, or CLL, or small lymphocytic leukemia, or SLL. The results will be presented at 10:15 am CST during the late-breaking abstract session on Tuesday, December 13. In this final PFS analysis, Brukinsa achieved superior PFS compared with ibrutinib, as assessed by both Independent Review Committee and investigator. The PFS results favored zanubrutinib consistently across major pre-defined subgroups including IGHV status and patients with del(17p)/TP53, regardless of IRC or investigator assessment, the company stated. "Brukinsa is the only BTK inhibitor to demonstrate superior efficacy over ibrutinib in any treatment setting; The ALPINE trial results demonstrate superiority for both PFS and ORR versus ibrutinib in relapsed or refractory CLL/SLL," said Mehrdad Mobasher, M.D., M.P.H. Chief Medical Officer, Hematology at BeiGene. "With nearly 30 months of follow up in this trial, we have seen a very consistent safety and tolerability profile for Brukinsa and look forward to sharing detailed results from this analysis at ASH."

09:47 EST Petrobras falls -8.9% - Petrobras is down -8.9%, or -96c to $9.79.

09:47 EST Best Buy rises 9.5% - Best Buy is up 9.5%, or $6.75 to $77.58.

09:47 EST Burlington Stores rises 17.0% - Burlington Stores is up 17.0%, or $26.82 to $184.47.

09:45 EST FDA investigating risk of severe hypocalcemia in patients receiving Prolia - The U.S. Food and Drug Administration announced it is investigating the risk of severe hypocalcemia with serious outcomes, including hospitalization and death, in patients with advanced kidney disease on dialysis treated with the osteoporosis medicine Prolia, or denosumab. "Our review of interim results from an ongoing safety study of Prolia suggests an increased risk of hypocalcemia, or low calcium levels in the blood, in patients with advanced kidney disease. Preliminary results from a separate internal FDA study further investigating hypocalcemia in dialysis patients treated with Prolia show a substantial risk with serious outcomes, including hospitalization and death," the FDA stated in a notice on its website. The FDA added: "When FDA first approved Prolia, we required the manufacturer, Amgen, to conduct a long-term safety study in women with postmenopausal osteoporosis and men with osteoporosis. Our review of the interim results from this ongoing safety study suggests an increased risk of hypocalcemia with Prolia in patients with advanced kidney disease. In addition, adverse event reports submitted to FDA showed severe and symptomatic hypocalcemia, including hospitalization and death, is occurring in patients with advanced kidney disease treated with Prolia. Preliminary results from a separate internal FDA study investigating the risk of hypocalcemia suggest that patients on dialysis treated with Prolia are at substantial risk for severe and symptomatic hypocalcemia, including hospitalization and death." Reference Link

09:41 EST TC BioPharm Ltd (ADR) trading resumes

09:38 EST Hainan Manaslu Acquisition to resume trading at 09:55ET - Trading in shares of Hainan Manaslu Acquisition is set to resume at 9:55 am ET, with quotation scheduled to resume at 9:50 am ET, according to Nasdaq. Shares had been halted ahead of the announcement that Able View has executed a business combination agreement with Hainan Manaslu.

09:36 EST Phoenix Motor, CATL enter long-term partnership - Phoenix Motor announced the signing of a non-binding Memorandum of Understanding with Contemporary Amperex Technology for the co-development of batteries for Phoenix Motorcars' product lines. The MOU will support the long-term supply of battery solutions and related products for Phoenix's commercial electric vehicles including Gen 4 vehicles, as well as the potential cooperation on Gen 5 and EdisonFuture models in the future. The two companies also agreed to explore the opportunity to deploy E-rolling chassis technology in Phoenix vehicle models.

09:35 EST IDBA Stock trading resumes

09:30 EST IDBA Stock trading halted, volatility trading pause

09:25 EST Able View executes business combination agreement with Hainan Manaslu - Able View announced that on November 21, 2022, Able View entered into a definitive business combination agreement with Hainan Manaslu Acquisition Corp. The parent company following the consummation of the business combination will be a new Cayman Islands holding company called Able View Global Inc., and will be led by Mr. Zhu Jian, Founder and Chief Executive Officer of Able View. Pubco's ordinary shares are expected to be listed on the Nasdaq Capital Market. Founded in Hong Kong in 2015, Able View Inc. is a leading cross-border brand management company focusing on beauty and personal care segments. Able View's full-service solution encompasses all aspects of the brand management value chain, covering marketing strategy, branding, digital and social marketing, omni-channel sales, customer service, oversea logistics, warehouse and fulfillment, to help global brands enter, grow and succeed in China. Leveraging its full-service capability and industry know-how, Able View usually engages with the brands as exclusive agent selling cross-border products to end customers in China across all channels. The transaction values the Combined Company at an estimated equity value on a pro-forma basis of approximately US$400 million, assuming no redemptions by HMAC's public shareholders in connection with the transaction. Assuming no redemptions by HMAC's public shareholders, it is estimated that the current shareholders of Able View will own approximately 80.3% of the issued and outstanding shares in the Combined Company at closing of the transaction. Following the consummation of the transaction, the Combined Company will report in the United States as a foreign private issuer, and, as such, will not be subject to the same disclosure and certain other obligations applicable to domestic public companies. In addition, the Combined Company expects to follow home country governance requirements, to the extent permitted by the rules of Nasdaq. The transaction has been approved by each of HMAC's and Able View's Board of Directors. The transaction is subject to the approval of HMAC's shareholders and other customary closing conditions and is expected to close in the second quarter of 2023.

09:21 EST Standard BioTools announces inducement grants under Nasdaq listing rule - Standard BioTools announced that the Compensation Committee of its Board of Directors, which is composed entirely of independent directors, granted equity awards effective as of November 20, 2022, under the Standard BioTools Inc. 2022 Inducement Equity Incentive Plan, as a material inducement to ten individuals entering into employment with Standard BioTools. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). In connection with the individuals entering into employment with Standard BioTools as new employees, none of whom were previously employees or directors of Standard BioTools, the individuals received awards totaling an aggregate of 235,200 restricted stock units. For each employee receiving an RSU Award, 1/4th of the total number of shares of common stock underlying each RSU Award will vest on November 20, 2023, and 1/16th of the shares will vest every three months thereafter until fully vested; provided, however, that if a vesting date would otherwise fall on a day when the national stock exchange upon which the shares are listed is not open for trading, vesting will occur on the first trading day thereafter. Vesting of the RSU Awards is subject to the employee continuing to be a service provider through each such vesting date, in addition to other terms and conditions of the Plan.

09:13 EST Calian Group to supply CCMEO with three Earth observation antennas - Calian Group announced that Natural Resources Canada's Canada Centre for Mapping and Earth Observation has once again entrusted Calian to provide three high-performance antennas for Inuvik and Gatineau. Valued at $12M, Calian will deliver two 7.3-meter tri-band antennas to Inuvik and one dual band antenna to Gatineau, including data reception and telemetry, tracking and command equipment. In all, three turnkey ground stations will be built and delivered. These ground stations will communicate with low earth orbit satellites for applications ranging from Earth observation, monitoring the environment, defence applications and disaster management. Work will commence immediately, tapping into local resources and businesses and will be completed in 2024.

09:10 EST Fortune Brands board approves separation of MasterBrand cabinets business - Fortune Brands announced that on November 21, its board of directors approved the previously announced separation of its cabinets business, MasterBrand, via a tax-free spin-off. The separation is expected to be complete on Wednesday, December 14 and will be achieved through the distribution of all outstanding shares of MasterBrand common stock to Fortune Brands common stockholders of record as of 5:00 PM, Central Time, on Friday, December 2. The distribution of MasterBrand's shares is expected to be completed after the market close on Wednesday, December 14, with Fortune Brands common stockholders receiving one share of MasterBrand's common stock for every share of Fortune Brands' common stock held on the record date.

09:09 EST ZeroFox launches PII Removal service - ZeroFox released PII Removal, a new Disruption service to help organizations combat data broker websites that include personal identifiable information of employees and executives listed for sale on publicly searchable databases. ZeroFox's enhanced Disruption PII Removal scans for and automates the takedown of customers' personal information on hundreds of data broker sites in an effort to proactively disrupt potential attacks before they happen.

09:06 EST ResMed completes acquisition of MEDIFOX DAN for EUR 958.6M - ResMed announced it has completed its EUR 958.6M acquisition of MEDIFOX DAN, a German leader in software solutions for a wide variety of out-of-hospital care providers. "We're excited to have closed this important expansion of our SaaS business, and to officially welcome MEDIFOX DAN to our ResMed SaaS team and global ResMed family," said ResMed CEO Mick Farrell. "MEDIFOX DAN is a German leader in software innovation, united with the rest of ResMed in its mission to improve tens of millions of people's lives through technology. Today, its strong offerings and dedicated staff expand ResMed's out-of-hospital SaaS business into new health sectors, and to build on our strong ResMed healthcare business in Germany, the world's second largest healthcare market in per capita spending." ResMed intends to retain MEDIFOX DAN's employees, locations, and business processes. MEDIFOX DAN will report into ResMed SaaS President Bobby Ghoshal.

09:04 EST WisdomTree Securities receives FINRA membership approval - WisdomTree announced that its wholly-owned subsidiary, WisdomTree Securities received membership approval as a broker-dealer from Financial Industry Regulatory Authority, FINRA, enabling WisdomTree Securities to facilitate transactions in blockchain-enabled funds offered in the WisdomTree Prime mobile application. "FINRA membership approval is a key regulatory milestone, for us, leading up to the launch of WisdomTree Prime, enabling us to act as an intermediary for customers to transact in new blockchain-enabled funds," said Jarrett Lilien, President and COO of WisdomTree. "As a regulation-forward company in blockchain-enabled finance focused on trust and security, this announcement is just another brick in the foundation we're building to unlock access to the exciting opportunity within structured and transparent products of the future. As always, our priority is to provide investors with the best product structure - which is ETFs today, and we believe blockchain-enabled funds are the best product structure of tomorrow."

09:03 EST Pokemoyo partners with Newtek Business Services - Pokemoto, Muscle Maker, Inc.'s (GRIL) expanding Hawaiian poke bowl restaurant concept, announced its partnership with Newtek Business Services Corp. (NEWT), a qualified lending source to assist current and prospective franchisees with securing funding to open Pokemoto eateries across the United States. "Ensuring that Pokemoto has lending solutions for prospective and current franchisees is extremely important in our model's core. Franchisees should be properly funded so that they can focus on opening and expanding their Pokemoto portfolios and Newtek provides a wide range of potential business solutions and services to help meet their needs said Michael Roper, Chief Executive Officer of Pokemoto. He continued, "Investing in any business is a big leap and we believe that partnering with Newtek will help our franchisees feel supported not only financially but in other areas of their businesses as well. We're confident in our partnership and believe we're providing a well-rounded package of resources which can be found on the Newtek portal on the franchising page of the Pokemoto website. Newtek has dedicated specialists ready to assist while providing round the clock support. We've ramped up our franchise marketing efforts and expanded our team in preparation to present more opportunities to prospective franchisees across the country. We believe this new lending partner will be beneficial to those looking for financing options to begin and expand their Pokemoto portfolios."

09:00 EST Western Acquisition Ventures Corp trading resumes

08:50 EST Conduent, BNY Mellon collaborate to launch Digital Integrated Payments Hub - Conduent Incorporated (CNDT) announced the launch of its new Digital Integrated Payments Hub enabling businesses and public sector agencies to access secure, faster, and cost-effective options to send, request or receive payments. By integrating the payment capabilities of BNY Mellon's (BK) trusted infrastructure, Conduent's new Digital Integrated Payments Hub speeds up refunds, rebates, and overpayment remediations from as many as 10 days to a matter of minutes, while providing the ability to conveniently and transparently track transactions.

08:41 EST BioLargo partner Ikigai begins sales of Pooph at Walmart - BioLargo, Inc. (BLGO) announced that the Pooph pet odor control product line is now available at select Walmart (WMT) stores. Pooph, which is based on BioLargo's proprietary odor control technology, is marketed by Ikigai Marketing Works, LLC through a national advertising campaign. Walmart is the first retailer for a planned national retail distribution, and begins with Pooph in over 600 stores across the United States.

08:36 EST Palisade Bio granted Fast Track designation from FDA for LB1148 - Palisade Bio announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track designation to LB1148 for the acceleration of time to return of bowel function following surgery. LB1148, is a broad-spectrum serine protease inhibitor which acts to neutralize digestive enzymes, with the potential to both reduce abdominal adhesions and accelerate the return of bowel function following gastrointestinal surgery. "Receiving Fast Track designation represents an important regulatory milestone for the Company. Although our current focus is on our adhesions study, this designation provides what we believe is a key component to our future clinical and regulatory strategies as we continue to formulate next steps for studying the return of bowel function," commented JD Finley, interim CEO of Palisade Bio.

08:35 EST Medtronic sees Q3 currency headwind of $460M-$510M

08:35 EST Medtronic sees exiting year with mid single digit top line growth

08:32 EST ToughBuilt enters distribution agreement with Lamed - ToughBuilt Industries announced that it has entered into a distribution agreement with Lamed. Lamed begins this agreement with 76 ToughBuilt SKUs and will stock the entire ToughBuilt product range. Michael Panosian, ToughBuilt CEO, commented, "We believe ToughBuilt is continuing to grow as a global brand with new distributors in many countries across the globe due to the quality of our innovative jobsite tools, gear, and storage solutions." He continued, "We are delighted to be supplying to Lamed and its loyal base of professional and DIY customers in Kazakhstan. We look forward to a long and mutually beneficial relationship with Lamed."

08:31 EST Medtronic not giving FY24 guidance yet, says CFO

08:27 EST Cuentas launches Free Wireless/Fintech Combo Offer - Cuenta announced it is launching its Free Wireless/Fintech Combo Offer to the first 100,000 subscribers starting Black Friday with the Major Arena Soccer League whose season starts the same day. Cuentas is the official fintech sponsor of the MASL and will have its brand present on MASL broadcasts in both English and Spanish languages.Cuentas' Free Wireless/Fintech Combo Offer will include Unlimited Talk & Text Mobile Phone services on one of the top 3 nationwide networks in the US with 200 MB of high-speed data included. The service will be free every month for each subscriber who opens a Cuentas Account with GPR card and maintains a minimum balance of $4.50.

08:24 EST TEN, Ltd. raises semi-annual dividend 50% to 15c per share - TEN's Board of Directors has approved a dividend of $0.15 per common share to be paid on December 20, 2022 to holders of record as of December 14, 2022. This distribution reflects the second payment for 2022 which is in line with TEN's semi-annual dividend policy and represents a 50% increase from the prior dividend of $0.10 per common share paid in July 2022. Inclusive of this upcoming distribution, TEN will have paid common shareholders half a billion dollars in dividends since its 2002 NYSE listing.

08:21 EST scPharmaceuticals announces pricing of $50M public offering - scPharmaceuticals announced the pricing of an underwritten public offering of 6,620,000 shares of its common stock at a public offering price of $5.25 per share and, to an investor in lieu of common stock, a prefunded warrant to purchase up to 2,905,000 shares of common stock at a purchase price of $5.249 per underlying share, for gross proceeds of approximately $50.0 million, before deducting underwriting discounts and commissions and other offering expenses and excluding the exercise of the pre-funded warrant. The prefunded warrant has an exercise price of $0.001 per share. All of the shares and the prefunded warrant are being offered by scPharmaceuticals. The offering is expected to close on November 25, 2022, subject to the satisfaction of customary closing conditions. SVB Securities and Cowen are acting as joint book-running managers for the offering. H.C. Wainwright & Co. and Maxim Group LLC are acting as co-managers for the offering.

08:19 EST Prosper Gold exercises option to buy 100% interest in Golden Sidewalk, Skinner - Prosper Gold has exercised its previously announced option under the Option Agreement dated August 9, 2020 between the Company and Sabina Gold & Silver Corp. to acquire a 100% interest in the Golden Sidewalk property and the Skinner property consisting of approximately 3,000 hectares of mineral claims, leases and patents in the Red Lake mining district of Ontario. In order to acquire the 100% Interest in the Properties, the Company has issued an aggregate of 1,500,000 common shares from its treasury to Sabina; paid an aggregate of $50,000 in cash to Sabina; and incurred expenditures on the Properties of not less than $2,600,000. Concurrent with the Company's previously announced acquisition of a 70% interest in the Properties on February 7, 2022, the Company and Sabina entered into Royalty Agreements pursuant to which Prosper Gold will pay to Sabina a 2.0% net smelter returns royalty on the proceeds from the production and sale of all ores, minerals, metals and materials mined or removed from the Golden Sidewalk Property and a 1.0% NSR on the proceeds from the production and sale of Products mined or removed from certain "Additional Property".

08:18 EST Medtronic CFO says company 'committed' to dividend

08:15 EST Society Pass, NusaTrip collaborates with Periksa.id - NusaTrip, the Indonesia-based Online travel agent and travel platform of Society Pass Incorporated, announces an official partnership with Periksa.id to enable and introduce flight search engine services in over 200 hospitals and clinics across 13 provinces in Indonesia. Periksa's network covers over 200,000 doctors, medical workers, and over 1.5 million daily patients. The partnership strengthens NusaTrip's commitment to developing more vibrant travel services for all consumers, business partners, and stakeholders in Indonesia and throughout SEA. "We believe that our technology and services can serve a broader range of travel demands and purposes than just leisure. Our collaborations pave the way and build a roadmap in contributing to Indonesia's wellness, health, and medical tourism industry," says Johanes Chang, NusaTrip's CEO. Joe further highlights NusaTrip's mission to become a world-class OTA and the most reliable partner that offers a wide range of travel and tourism-related products, services, and experiences to our customers and business partners globally. NusaTrip aims to improve the efficiency of the emergency travel or medical evacuation for patients in need and to support the home care or onsite health care services offered by many doctors, hospitals, and clinics. As NusaTrip's partner of choice, the Indonesian health technology company, Periksa.id has been providing an extensive solution to digitize and improve the quality of healthcare facility services in Indonesia.

08:13 EST Base Carbon selected by Danish Red Cross as partner on blue carbon projects - Base Carbon, through its subsidiary Base Carbon Capital Partners Corp, has entered into a letter of intent with the Danish Red Cross to scope and assess - and potentially develop - one or more mangrove-related carbon reduction projects in Southeast Asia which are anticipated to follow VERRA "Tidal Wetland and Seagrass", methodology. The parties have committed to work together until at least October 2024 with respect to such potential projects in the region. Potential projects related to the prospective partnership will be jointly funded by the Danish Red Cross including other Red Cross affiliated entities. The parties anticipate that any project will be insured by Dunant Re IC Limited, an insurance company established by the Danish Red Cross and Replexus. The Company anticipates providing regular updates as the parties work together."This partnership is consistent with Base Carbon's mandate to work with leading organizations on carbon projects with strong economics and social benefit additionalities. The Red Cross Movement, with its scale and breadth is ideally suited to execute carbon reduction and removal projects. Base will invest and contribute technology to materialize these projects," stated Philip Hardwick, COO of Base Carbon.

08:11 EST SLB announces award to its OneSubsea business - SLB announced an award to its OneSubsea business and Subsea Integration Alliance of a large contract by bp for its Cypre gas project offshore Trinidad and Tobago. The contract scope covers the engineering, procurement, construction, and installation of the subsea production systems and subsea pipelines. The award represents Subsea Integration Alliance's first fully integrated EPCI single contract with bp and the alliance's first development in the Caribbean nation. The Subsea Integration Alliance team delivered the initial front-end engineering and design phase for the project and will now transition into the full EPCI phase. Offshore installation is scheduled to commence in 2024. OneSubsea, the subsea technologies, production, and processing systems business of SLB, will deliver the subsea production systems, which will include seven horizontal subsea tree systems, subsea controls and connection systems, distribution and control systems and aftermarket services. Subsea7, also part of Subsea Integration Alliance, will deliver the subsea pipelines for the project.

08:11 EST Lexagene Holdings completes statement of work for biopharma company - LexaGene announces the completion of a validation study with a major biopharma company that recently purchased a MiQLab System for the possible use of the technology in its manufacturing processes. Dr. Jack Regan, LexaGene's CEO and Founder commented, "We are very pleased with how quickly this study was completed and the quality of the data generated. This validation study showed the MiQLab System to be sensitive, reliable, reproducible, tolerant to materials commonly used or produced in the manufacturing process, and it provides quantitative information on targeted contaminants. Furthermore, the data proved the MiQLab System is comparable to gold standard techniques performed by skilled scientists. These benefits and the automated nature of the MiQLab System make in-line screening for manufacturing contaminants possible. Such in-line screening would allow for more rapid detection of contaminants, which mitigates the risk of significant losses and improves the productivity of the plant and the safety of their products." Dr. Regan continued, "Now that the study is complete, I look forward to discussing with our biopharma customer the next steps that are needed to get our technology broadly adopted for their manufacturing testing needs." The validation study was conducted using MiQLab Systems equipped with MiQLab Microbial QC Panels that screen processed samples for Cutibacterium acnes, Escherichia coli, Staphylococcus, Streptococcus and Mycoplasma.

08:09 EST VBI Vaccines presents data from VBI-1901 in recurrent GBM - VBI Vaccines announced that additional biomarker data from the Phase 1/2a study of VBI-1901, the Company's cancer vaccine immunotherapeutic candidate in recurrent glioblastoma were presented at the 27th Annual Meeting and Education Day of the Society for Neuro-Oncology on Friday, November 18. In the study arms that assessed high-dose VBI-1901 adjuvanted with granulocyte-macrophage colony-stimulating factor: Two partial tumor responses were observed in patients - one patient with a PR remained on treatment protocol for more than 28 months, reaching survival of at least 32 months as of November 1; An additional five patients demonstrated stable disease for a sustained period of time. All tumor responders reached a minimum survival of 12 months Median overall surviva was 12.9 months, comparing favorably to 8-month mOS for monotherapy standard-of-care1 New data from extensive biomarker panels continue to suggest that normal baseline CD4+/CD8+ T cell ratios, along with boosting of cytomegalovirus gB specific antibody responses, were correlated with tumor and clinical responses. Six out of seven tumor responders had normal baseline CD4+/CD8+ ratios, and all seven tumor responders saw boosting of gB antibodies after treatment with VBI-1901. Higher peak frequencies of CMV antigen-specific CD4+ T cells were observed in patients with tumor responses compared to non-responders, suggesting significant function of CD4+ T cells in controlling tumor growth. "We look forward to initiating randomized, controlled evaluation of VBI-1901 in the recurrent setting in early 2023." This dataset continues to build upon data first shared at ASCO 2021, which resulted in Fast Track Designation granted by the U.S. Food and Drug Administration in June 2021. The data have subsequently been updated at the World Vaccine & Immunotherapy Congress in December 2021 and at ASCO 2022.

08:07 EST Hamilton Thorne says Q4 bookings 'continued to be strong' - CEO David Wolf added, "Looking forward into the balance of 2022, we continue to feel that we are in a strong position. We expect solid sales performance, based on the positive industry trends in our field and as demand and growth have returned to pre-pandemic levels in nearly every market that we serve. Q4 bookings continued to be strong and barring new supply chain issues, we expect to continue to achieve well above market organic growth. We feel that we are well positioned to continue to execute on our strategy of driving long-term growth and EBITDA expansion by investing in our organic growth, while building scale, enhancing our product offerings, and expanding our geographic and direct sales footprint through acquisitions. We have an extensive pipeline and are actively working on multiple acquisition opportunities. With $15.7 million in cash, $11.6 million in unused lines of credit, and further debt capacity, we are well positioned to continue to execute on our acquisition program."

08:07 EST NFL, Genius Sports announce new licensing agreements with three sportsbooks - The National Football League and Genius Sports announced new licensing agreements with three sportsbooks to distribute live video streams of NFL matches to their customers in Canada. Bet365, Bet99 and Rivalry have all been granted the rights to provide their customers in Canada with low latency video streams of all regular and post-season matches on the NFL through Genius Sports' fully integrated Watch & Bet solution. Genius Sports will utilize its machine learning and live streaming technologies to power video experiences for millions of sportsbook customers in Canada, including engaging new ways to track bets and follow the live action. The NFL appointed Genius Sports in April 2021 as its exclusive distributor of real-time official play-by-play statistics, proprietary Next Gen Stats data, and the League's official sports betting data feed to media companies and sportsbooks in regulated international markets. This partnership included the rights for Genius Sports to distribute low latency video feeds to sportsbooks in key international markets, which now includes Canada. Each of the three licensees will combine low latency video feeds with the league's official data and access to exclusive data-driven advertising inventory, to provide their Canadian customers with the highest quality NFL betting experiences.

08:06 EST TC Biopharm doses first three patients in Phase 2b clinical trial of OmnImmune - TC Biopharm announced the dosing of its first three patients within its Phase 2b clinical trial of OmnImmune, an allogeneic unmodified cell therapy focused on treating Acute Myeloid Leukemia, or AML. The initial 5 patients in the trial are deemed a "safety cohort", spaced two weeks apart with safety review by an oversight board to confirm no drug related toxicity issues, subsequent to 5 patients being dosed the study will advance to open enrollment. This safety cohort is in line with TCBP's step-wise clinical trial advancement, moving from donor matching in the Phase 1b to a universal donor model with no HLA matching of donor to patient. TC BioPharm's Phase 2B trial, dubbed ACHIEVE, will enroll adults diagnosed with AML who have either relapsed or are refractory to prior treatments as well as a cohort for patients with myelodysplastic syndromes (MDS), conditions that can occur when the blood-forming cells in the bone marrow become abnormal. The trial is expected to enroll approximately 37 patients.

08:06 EST Medtronic CEO: Operating environment remains challenging - Comments taken from Q2 earnings conference call.

08:05 EST American Eagle sees Q4 brand revenue down mid single digits - The company said, "For the fourth quarter, the company is guiding brand revenue down in the mid single digits, and expects brand comps to be consistent with the third quarter. The company is also guiding fourth quarter gross margin in the range of 32% to 33%, at the higher end of previous guidance. While significant progress has been made in right-sizing inventory, management is taking a cautious view given what is likely to be a highly promotional Holiday season. Management continues to drive expense reductions across store payroll, corporate expense, professional services and advertising. The company remains on track to deliver $100 million in reductions to the original plan and expects SG&A dollars in the fourth quarter to be approximately flat to last year."

08:04 EST InnovAge announces release of CMS sanction in Sacramento center - InnovAge announced that the Centers for Medicare & Medicaid Services, CMS, has determined that effective immediately the sanction is released from InnovAge in Sacramento, California and it will return to normal enrollment status for Medicare-eligible participants. The California Department of Health Care Services continues to conduct its validation audit and has not lifted the state sanction. The DHCS audit outcome determines InnovAge's ability to enroll Medicaid recipients, which is required to enroll seniors with both Medicare and Medicaid. "Today's announcement is a step in the right direction, and we are proud of our team for the work they have done to address the audit findings and strengthen our end-to-end operations," said InnovAge President and Chief Executive Officer Patrick Blair. "We recognize there is still work to do, and we look forward to working with both CMS and our state partners to ensure we are providing the highest quality care and access to all Sacramento-area eligible seniors."

08:03 EST AppHarvest kicks off third season ahead of schedule with shipments of tomatoes - AppHarvest announced it has kicked off the third season of harvesting ahead of schedule with commercial shipments of tomatoes from its 60-acre high-tech indoor farm in Morehead, Ky. As AppHarvest works to quadruple its number of farms in 2022, the company continues construction on a fourth facility, a 60-acre farm in Richmond, Ky., that will grow tomatoes. "With the experience of two seasons of harvests, the Morehead farm is seeing significantly improved quality and yield, which largely can be attributed to task completion rates of crop care specialists meeting and sometimes exceeding 100% of goal," said AppHarvest Founder & CEO Jonathan Webb. "We're developing a tenured workforce and seeing benefits of promoting from within to help drive efficiency and quality from folks who have grown the business with us from the ground up." The AppHarvest team has continued to enhance training with routine quality checks of crop care tasks, which facilitates quick retraining if needed.

07:55 EST Best Buy jumps 8% to $76.17 after Q3 earnings beat and comps outlook update - Shares of Best Buy are up about 8% or $5.34 to $76.17 in pre-market trading after the company beat on Q3 earnings and revenue. Best Buy also updated its FY23 comparable sales outlook to "down approximately 10%" from prior assumption of a "decline in a range around 11%".

07:54 EST Celcuity to present additional data for gedatolisib at SABCS - Celcuity announced that an abstract accepted for a Spotlight Poster presentation at the 2022 San Antonio Breast Cancer Symposium is now available on the SABCS website. The 2022 San Antonio Breast Cancer Symposium is being held virtually and in-person from December 6-10, 2022. The presentation will include updated efficacy and safety data and sub-group analysis by PIK3CA mutation status in the four expansion arms of a Phase 1b study of gedatolisib plus palbociclib and endocrine therapy in women with hormone receptor positive advanced breast cancer. The primary endpoint was investigator assessed objective response rate. Secondary endpoints included safety, duration of response and progression free survival. Promising ORR and PFS were seen in all arms, regardless of PIK3CA mutation status. Arm D, which treated patients whose disease progressed on a CDK4/6 inhibitor, reported ORR of 63% overall, 73% in PIK3CA-mutation patients, and 60% in PIK3CA-wild type patients; overall PFS was 12.9 months. Arm A, which evaluated patients who were treatment-naive in the advanced disease setting, reported ORR of 85% overall, 81% in PIK3CA-wild type patients, and 100% in PIK3CA-mutations patients; median PFS was not reached after a median follow-up period of 33.1 months. These preliminary findings demonstrate promising activity for gedatolisib plus palbociclib and endocrine therapy in patients who were CDK4/6 inhibitor-naive and in those whose disease progressed on or after treatment with a CDK4/6 inhibitor, regardless of PIK3CAmutation status. Arm D results provide a strong rationale for Celcuity's Phase 3 clinical trial in patients with advanced breast cancer whose disease progressed on or after CDK4/6 therapy. The encouraging results in treatment-naive advanced breast cancer patients warrant further evaluation of gedatolisib in combination with a CDK4/6 inhibitor and endocrine therapy in early line settings, including front-line, neoadjuvant, or adjuvant indications.

07:49 EST Amarc announces Minerawl Property Earn-in Agreement with Boliden - Amarc Resources entered into a Mineral Property Earn-in Agreement with Boliden Mineral Canada. Under the terms of the Agreement, Boliden may earn up to a 70% ownership interest, by making staged exploration and development investments, in Amarc's 100% owned DUKE porphyry Cu-Au district in central British Columbia. Amarc is the operator of the project. Amarc's 678 km2 DUKE District is located 80 km northeast of Smithers within the Babine Region, one of BC's most prolific porphyry Cu-Au belts, which hosts Noranda Mines' past producing Bell and Granisle Cu-Au mines and the advanced stage Morrison Cu-Au deposit. Significant infrastructure exists in the region, servicing an active forestry industry and also former mining activity. Central to Amarc's extensive mineral tenure is the DUKE Deposit discovery that is located 30 km north of the Bell Mine. In addition to the DUKE Deposit, some 12 new porphyry Cu deposit targets have been identified on Amarc's mineral claims. Under the terms of the Agreement Boliden has a two-staged option to earn up to a 70% interest in the DUKE District. To earn an initial 60% interest Boliden must fund CDN$30 million of exploration and development expenditures within four years of the effective date of the Agreement, of which CDN$5 million is a committed amount to be spent in 2022 and early 2023. Amarc will be the operator during this initial earn-in stage. Upon earning a 60% interest, Boliden can elect to earn an additional 10% interest in the Duke District, for an aggregate 70% interest, by funding an additional CDN$60 million of exploration and development expenditures at a minimum rate of CDN$10 million per year over the ensuing six years. Once Boliden has earned a 60% interest it will also have the right to become the operator. Upon Boliden finalizing its earned ownership interest, Amarc and Boliden will form either a 60:40 or 70:30 unincorporated joint venture to further advance the Duke District. At that stage each party will be responsible for funding its own pro-rata share of project costs, or be subject to customary equity dilution, converting to a capped royalty if it falls below a 10% participating interest.

07:44 EST PeoplesBank donates building to Glen Rock Borough - PeoplesBank, A Codorus Valley Company, a subsidiary of Codorus Valley Bancorp, is donating its PeoplesBank Building to the Borough of Glen Rock Pennsylvania. PeoplesBank's President and CEO, Craig Kauffman, spoke with the borough council ahead of the donation and expressed PeoplesBank's gratitude toward Glen Rock, "As the birthplace of PeoplesBank, Glen Rock holds a special place in the hearts of every PeoplesBank associate. The donation is another example of the bank's long-term commitment to the community and our commitment to memorializing the legacy of PeoplesBank's contribution to the prosperity of the area."

07:42 EST Savaria opens Queretaro City, Mexico factory - Savaria Corporation recently hosted a grand opening celebration of its new 95,000-square-foot factory in Queretaro City, Mexico. Strategically located to better serve the growing demand of the Savaria US-based dealer network, the new building was constructed over the past seven months in Queretaro City, a fast-growing economic center. The facility is modelled after Savaria Huizhou, Savaria's highly successful operation providing subassembly services. The proximity to the US market will reduce lead times and freight costs, as well as adding overall capacity to meet revenue growth. A grand opening celebration was held on November 12 welcoming employees and their families. Savaria is hiring additional staff with a goal of 100 employees by the end of 2023. Production of the Savaria Multilift, a popular vertical platform lift for home and commercial applications, is already underway.

07:41 EST Abercrombie chairperson Terry Burman to step down, Nigel Travis to succeed - Abercrombie & Fitch announced a change in its Board of Directors as part of a leadership transition. After five years in the position and in connection with his plans to retire as a Director, Terry Burman will step down as Chairperson of the Board at the conclusion of the company's fiscal year ending on January 28, 2023, and will not stand for re-election at the Company's 2023 Annual Meeting of Stockholders. Nigel Travis, current Director and Chair of the Nominating and Board Governance Committee of the Board, will assume the role of Chairperson effective January 28, 2023. Mr. Burman joined the Board in January 2014 and was appointed Non-Executive Chairperson in February 2018. Mr. Travis joined the Board as an independent director in February 2019.

07:39 EST IntelGenx receives FDA PDUFA date for RIXAFILM - IntelGenx announced that the U.S. Food and Drug Administration, FDA, has accepted for review its Class 2 response to the 2020 Complete Response Letter for its 505(b)(2) New Drug Application, NDA, for RIZAFILM VersaFilm. The FDA has assigned a Prescription Drug User Fee Act, PDUFA, goal date of April 17, 2023 for completion of the review of the RIZAFILM NDA. "We are pleased to receive confirmation that the FDA is commencing its review of our NDA resubmission, and are looking forward to continuing to work with the Agency to make RIZAFILM VersaFilm available to acute migraine patients in the United States," commented Dr. Horst G. Zerbe, CEO of IntelGenx.

07:37 EST Zapp to become publicly traded via combination with CIIG Capital Partners II - CIIG Capital Partners II and Zapp Electric Vehicles have entered into a definitive business combination agreement. Upon closing of the transaction, the combined company, Zapp Electric Vehicles Group Limited, a Cayman Islands exempted company, is expected to list its ordinary shares on the Nasdaq under the ticker symbol "ZAPP". Zapp was founded in 2017 by a group of mobility experts with a vision and commitment to bring high-performance to urban mobility through original, advanced design with an emphasis on safety, quality, customer experience and full-cycle sustainability. Zapp's first product to enter the market, the i300, has received widespread acclaim and consumer interest for its embodiment of these values. Unlike other urban electric bikes, the i300 is built around an innovative exoskeleton architecture and is powered by an advanced British-designed electric motor, which enables it to match the acceleration of high-performance motorcycles in a step-through architecture. A lightweight alloy and composite bodywork allow for a slim total weight of just 108 kg. The i300's interior permanent magnet electric motor and carbon fiber belt drive combine to drive acceleration from 0 to 30 mph in just 2.3 seconds and from 0 to 60 mph in 5.0 seconds. The i300 utilizes ultra-portable lithium-ion battery packs weighing just 6 kg each. The battery packs can be charged from 20% to 80% via standard 220v/110v wall sockets in under 40 minutes. The portability of the battery packs makes the i300 easy to charge anywhere and at any time without reliance on a public charging network. The i300 is well-positioned to handle the average daily commute for urban drivers. Zapp expects to implement a high-quality direct-to-customer experience called DSDTC. Once a customer places an online order, their selected model will be processed and conveniently delivered directly to their home by "Zappers," who are independent service agents who perform deliveries in dedicated and purpose-designed plug-in hybrid service vans. Zappers also provide at-home inspection, service and support throughout the life of the vehicle. As part of Zapp's full-stack e-commerce platform, customers are expected to have access to highly competitive leasing and insurance solutions.Zapp also uses a Gen-2 sustainability design approach that requires fewer components and assembly steps and bodywork made from composites with green-to-make materials, with substantially all components being recyclable . The combined company will have an estimated fully-diluted post-transaction enterprise value of $573 million, consisting of an estimated equity value of $852 million, $274 million in new cash to the balance sheet, and $5 million in existing cash. Cash proceeds raised will consist of CIIG II's approximately $294 million cash in trust, net of redemptions. With no minimum cash condition, the cash in the CIIG II trust account is anticipated to support the Company's growth capital needs, including Zapp's production, marketing and sales efforts. It is intended that 100% of existing Zapp shareholders will roll over their equity and, assuming no redemptions and full rollover, own approximately 59% of the pro forma equity of the combined company in connection with the transaction. The business combination has been approved by the boards of directors of both Zapp and CIIG II and is expected to close in the first half of 2023, subject to stockholder approvals and other customary closing conditions.

07:33 EST Dick's Sporting CEO says 'We delivered an exceptionally strong third quarter' - Lauren Hobart, President and CEO said, "We delivered an exceptionally strong third quarter with our comps increasing 6.5% and EBT margin of 10.3%, which was over three times our 2019 non-GAAP rate. DICK'S is a growth company, and our Q3 sales results are powerful evidence of our sustainable growth story. Because of our continued strong performance, quality of inventory and the confidence we have in our business, we are raising our full year 2022 outlook."

07:28 EST Vox Royalty acquires Australian gold royalty over Cardinia gold project - Vox Royalty (VOXR) executed a binding royalty sale and purchase agreement dated November 21, 2022 with Gloucester Coal and acquired Gloucester's Cardinia development-stage gold royalty in Western Australia for A$450,000 cash. The Company is also pleased to announce that it has completed the acquisition of First Quantum Minerals Ltd.'s (FQVLF) Canadian royalty portfolio, previously announced on November 10, 2022, which closed on November 21, 2022. The acquired royalty, previously produced on a bulk sampling basis, is a 1% Gross Value of Sales royalty above 10,000oz cumulative gold production on mining lease M37/86, which is operated by Kin Mining, and is part of Kin's flagship Cardinia Gold Project, which is located 30km east of Leonora in Western Australia. The Cardinia Royalty was created in 1993 pursuant to an Option Agreement between Sons of Gwalia Ltd and Centenary International Mining Ltd, the latter of which became CIM Resources Ltd, and eventually, Gloucester. Riaan Esterhuizen, Executive Vice President - Australia stated: "This overlooked 1993 vintage gold royalty is Vox's ideal low-cost acquisition - a fully-permitted and shovel-ready gold project, located in the prolific Leonora district of Western Australia within trucking distance of 4 existing mills with over 10Mtpa processing capacity. This transaction was originated using Vox's proprietary royalty database of over 8,500 royalties, to identify an overlooked gold royalty inherited through a broader 2012 corporate acquisition. Regional consolidation within the Leonora region is underway with Genesis Minerals' acquisition of Dacian Gold and merger talks ongoing between Genesis and St Barbara, all of which bodes well for Kin Mining's prospects at the Cardinia Gold Project." Closings of the Transaction and the acquisition of the FQM royalty portfolio occurred on November 21, 2022, with Vox using cash on hand to fund the payment of the Transaction.

07:23 EST Arvinas says ARV-471 achieves clinical benefit rate of 38% in evaluable patients - Arvinas (ARVN) announced initial results from the Phase 2 cohort expansion portion of a phase 1/2 study with ARV-471, a novel PROTAC estrogen receptor protein degrader. ARV-471 is being co-developed with Pfizer Inc. (PFE) for the treatment of patients with locally advanced or metastatic ER positive / human epidermal growth factor receptor 2 negative breast cancer. This disclosure was originally planned for December 8, 2022. However, on November 21, 2022, the 2022 San Antonio Breast Cancer Symposium incorrectly published the abstract, omitting a key safety data table, and inadvertently released the corresponding full data presentation on the SABCS website. These full data are scheduled to be presented on December 8, 2022 at 9:00 a.m. CT in an oral presentation titled "ARV-471, a PROTAC estrogen receptor degrader in advanced ER-positive/human epidermal growth factor receptor 2-negative breast cancer: phase 2 expansion of a phase 1/2 study." As a result of the early release of the full data presentation, Arvinas will host a conference call and webcast today, November 22, 2022, at 4:30 p.m. ET to discuss these data. In the VERITAC trial, ARV-471 shows a favorable tolerability profile and demonstrates a clinical benefit rate of 38%, the primary endpoint in the trial. These results are consistent with the Phase 1 portion of this trial. Patients in VERITAC had a median of four lines of prior therapies, in a population where 100% of patients were treated with prior cyclin-dependent kinase inhibitors, 79% with prior fulvestrant, and 73% with prior chemotherapy. At the time of data cutoff, ARV-471 administered at 200 mg and 500 mg demonstrated: Antitumor activity in 100% CDK4/6 inhibitor-pretreated patients, as measured by a CBR of 38% in all patients and 51.2% in patients with mutant ESR1 tumors. Preliminary median progression-free survival of 3.7 months, a key secondary endpoint, in all evaluable patients and 5.7 months in patients with mutant ESR1 tumors. A favorable tolerability profile, with the majority of treatment-related adverse events reported as Grade 1 or 2. Anticipated 2022/2023 Milestones: Initiate a Phase 3 trial with ARV-471 as a second-line treatment in patients with ER+/HER2- metastatic breast cancer; Initiate a Phase 3 trial with ARV-471 in combination with palbociclib as a first-line treatment in patients with ER+/HER2- metastatic breast cancer; Initiate the first two cohorts and initiate additional arms with other targeted therapies in the ongoing Phase 1b combination trial; Present data from the Phase 1b combination trial with palbociclib at a medical conference.

07:16 EST Rio2 Limited sells non-core royalty package to Osisko Gold for $5M - Rio2 (RIOFF) announces that it has entered into a binding agreement to sell a package of Chilean royalty interests to Osisko Gold Royalties Ltd. (OR) for aggregate consideration of $5,000,000. The Royalty Sale provides for the sale of Rio2's 1.5% royalty on the Anocarire Project and its 1.25% royalty on the Horizonte Project, both located in Chile. Rio2 is currently in an administrative appeal process with the Chilean Government with respect to the rejection of the Environmental Impact Assessment for the development of its Fenix Gold Project, as previously outlined in a press release dated September 7, 2022. The Royalty Sale is subject to customary conditions precedent and is expected to close in the coming days.

07:12 EST Oxford Biomedica appoints Mathias as CEO - Oxford Biomedica announces the appointment of Dr Frank Mathias as Chief Executive Officer, CEO, and Board Director, effective March 2023. Since 2016 Mathias has served as CEO of Rentschler Biopharma SE, which he has successfully developed into a leading global, full-service CDMO. Dr Roch Doliveux will remain as Interim CEO of Oxford Biomedica until March 2023, at which point Dr Mathias will fully take over the role of CEO and Dr Doliveux will resume the role of Non-Executive Chair.

07:10 EST React Gaming subsidiary Parabellum Esports partners with XP League - React Gaming Group announce that its subsidiary Parabellum Esports has partnered with XP League. Through this partnership, select XP League teams will be able to play under the Parabellum name and wear a co-branded jersey, helping to cement XP League as the premier youth esports organization aligned with professional esports. The partnership will also be a launching pad for the Parabellum Academy, which will work directly with players, creators and enthusiasts who want to enter the esports space. Parabellum Academy is currently working on developing online courses, mentorship programs and academy teams, in line with its professional competitive teams in Rainbow Six, Rocket League and CSGO. Parabellum Academy's launch is planned for Q1 2023. "Our strategy with Parabellum Esports is to build our own professional team ecosystem from the ground up, with recruitment, training and development of competitive professional teams in various leagues that will also complement our current rosters and allow us to expand our activities," said Leigh Hughes, CEO of React Gaming. "This will also serve the purpose of enhancing Parabellum's brand recognition and increasing sponsorship and prize money opportunities, with the goal of monetizing this growing asset with minimal investment of capital."

07:10 EST Sidus Space signs MOU with Capital C for maritime satellite design, surveillance - Sidus Space has signed a memorandum of understanding, or MOU, with Capital C. As part of the agreement, Sidus will assist in developing, delivering, and maintaining surveillance and tracking systems with software that utilizes satellite imagery, sensor data, and data delivery. Sidus will provide continued access to LEO satellite communications systems as well as the design and manufacture of specialized marine parts as a preferred vendor to Capital C. This partnership blends Sidus' rich manufacturing heritage with areas of strategic growth including satellite technology and data subscriptions as it prepares to launch its proprietary, partially 3-D printed, LizzieSat satellites in 2023. The use of 3-D printing, as opposed to traditional manufacturing, is a sustainable method that reduces waste, resources, cost and time. Capital C is a design and technology company specializing in designing yachts that are at the forefront of sustainability and are Carbon Positive, incorporating advanced technology, robotics, safety systems and autonomous systems within its designs, which are also focused on environmentally friendly and greatly reduced emissions capabilities.

07:07 EST Marker Therapeutics announces FDA clearance of IND for MT-601 - Marker Therapeutics announced that the U.S. Food and Drug Administration, FDA, has cleared the Company's Investigational New Drug, IND, application for MT-601, a multi-tumor-associated antigen-specific T cell product targeting six antigens, for the treatment of patients with locally advanced unresectable or metastatic pancreatic cancer in combination with front-line chemotherapy. Marker intends to initiate a multicenter Phase 1 trial for the treatment of patients with locally advanced unresectable or metastatic pancreatic cancer in combination with front-line chemotherapy in 2023. Compared to the TACTOPS study, Marker is using a new, streamlined manufacturing process for MT-601. This new manufacturing process has already demonstrated major improvements to MT-401, Marker's multiTAA-specific T cell product for AML. The new manufacturing process allows production in 9 days compared to the original process of greater than30 days. "The FDA's clearance of our IND for MT-601 is a significant milestone for Marker as we prepare for our third planned clinical trial evaluating our multiTAA-specific T cell therapy next year," said Peter Hoang, President and Chief Executive Officer of Marker Therapeutics. "Our pioneering multi-antigen approach to cancer treatment has the potential to significantly benefit patients, and we are pleased to advance development of our pancreatic cancer program through the initiation of our Company-sponsored Phase 1 trial in 2023."

07:06 EST ObsEva announces sale of Ebopiprant license agreement to XOMA for up to $13M - ObsEva SA (OBSV) announced the sale of all of the Company's rights to Ebopiprant to XOMA (XOMA) for an upfront payment of $15M and future milestone payments of up to $98M. ObsEva expects the sale proceeds to resolve its current over-indebtedness position, enabling the Company to withdraw the Company's previously announced moratorium proceedings before Swiss courts, as well as position the Company to regain compliance with minimum stockholders' equity requirements for continued listing on The Nasdaq Stock Market. Under the terms of the agreement with XOMA, ObsEva has sold and assigned all its rights to Ebopiprant, an investigational, orally active, selective prostaglandin F2alpha receptor antagonist being evaluated as a potential treatment for preterm labor by reducing inflammation and uterine contractions, to XOMA, including the Company's license agreements with Organon and Merck KGaA, Darmstadt, Germany, and the intellectual property estate. In addition to the $15 million received in upfront proceeds, ObsEva is eligible to receive up to $98 million upon the achievement of certain development and regulatory milestones and sales milestones under the Company's license agreement with Organon for Ebopiprant that was sold to XOMA in the transaction. In conjunction with the closing of the transaction, ObsEva and JGB Management entered into a Consent and Amendment Agreement, whereby JGB consented to ObsEva's transaction with XOMA, and ObsEva agreed to maintain restricted cash equal to the total amount of outstanding principal under the outstanding convertible notes held by certain funds and accounts managed by JGB, subject to reduction upon conversion or payoff of the notes, and agreed to amend the maturity date for each note to December 31, 2023.

07:03 EST Actelis Networks authorizes up to $1M share repurchase program - Actelis Networks announced that its Board of Directors has authorized a share repurchase program pursuant to which the Company may repurchase up to $1 million of its outstanding shares of common stock. The Board of Directors authorized the Company to purchase its common stock from time to time on a discretionary basis through open market purchases, privately negotiated transactions or other means, including trading plans intended to qualify under Rule 10b-18 of the Securities Exchange Act of 1934, as amended, in accordance with applicable federal securities laws and other applicable legal requirements. "We believe that there is a disconnect between our current share-price and the fair value of our stock," said Tuvia Barlev, CEO of Actelis. "2022 has been a year of investment and growth for Actelis and with our continuous efforts, we look forward to further accelerate our growth. The authorization of this Share Repurchase Program reflects our leadership's confidence in the trajectory of the organization and our ability to generate long-term shareholder value."

07:01 EST Regeneron announces EC approval of Libtayo - Regeneron Pharmaceuticals announced that the European Commission approved Libtayo as monotherapy for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.

06:54 EST Tuesday Morning withdraws previous FY23 guidance - On November 4, the company announced changes to its leadership team including the appointment of Andrew Berger to CEO along with his assumption of CFO responsibilities. Given this recent change in leadership, the company is withdrawing its previous guidance for full year fiscal 2023.

06:51 EST Burlington Stores CEO: 'We think the outlook for 2023 is very positive' - Michael O'Sullivan, CEO, stated, "In Q3 we achieved sales and earnings that were within our guidance range, but we are not happy with this performance. As we said on our August earnings call, as an off-price retailer we should be able to perform better in this environment despite the significant macro headwinds. Recent results from other off-price retailers reinforce this view." O'Sullivan continued, "As we described in August, the consumer's frame of reference for value shifted significantly in 2022, but we did not respond aggressively enough to this shift. So, in Q3 we took significant steps to improve the value and mix of our assortment. These actions have driven an improvement in our trend from mid-October through November. We are encouraged by this but given the external risks we are maintaining our guidance for Q4." Looking further ahead, O'Sullivan said, "While we acknowledge that there are risks and uncertainties, we think the outlook for 2023 is very positive. We anticipate that the economic and competitive environment could set up very well for off-price. We also recognize that we will be lapping our own execution mistakes and under-performance from 2022. Based on these factors we believe that we can start to drive significant sales, margin, and earnings recovery next year."

06:33 EST Lion Electric enters four-year supply pact with lithium-ion battery supplier - Lion Electric announced that it has entered into a four-year supply agreement with a supplier for the supply of lithium-ion battery cells to be used for the manufacturing of batteries for electric vehicles. Subject to the terms and conditions of the cell supply agreement, the supplier has committed to supply, and Lion has committed to purchase, on a non-exclusive basis, lithium-ion battery cells at escalading volumes over calendar years 2023 and 2024, at agreed upon prices, subject to adjustments, including to account for increases in the prices of raw materials and changes in specifications. Volumes and unit prices for calendar years 2025 and 2026 remain to be agreed upon by the parties. The cell supply agreement currently provides that 39M lithium battery cells are to be purchased by Lion in total over calendar years 2023 and 2024, subject to, among other things, the supplier completing its internal cell qualification processes to validate satisfaction of Lion's specification requirements. The cell supply agreement provides for termination rights and penalties in favor of each party in the event that a specified percentage of the volume commitments set forth in the contract are not met for each applicable period defined thereunder.

06:08 EST ReneSola names Himanshu Shah chairman - ReneSola announced that Himanshu Shah, founder and CIO of Shah Capital was appointed as chairman of the board of directors. In addition, the company made the following changes to the leadership and members of its board committees, effective immediately. Shah Capital is a long-term stakeholder and has over 22% ownership of ReneSola Power. Himanshu joined ReneSola Power as a director in March.

05:56 EST Paramount terminates deal to sell Simon & Schuster to Penguin Random House - In a regulatory filing, Paramount Global said that on November 2, 2021, the U.S. Department of Justice filed suit in the United States District Court for the District of Columbia to block the Sale of Simon & Schuster business to Penguin Random House LLC and on October 31, 2022, the Court ruled in favor of the DOJ, enjoining the Sale. Following the Decision, on November 21, 2022, Paramount terminated the Purchase Agreement in accordance with its terms. Penguin Random House is obligated to pay a $200M termination fee to Paramount. Paramount said: "Simon & Schuster remains a non-core asset to Paramount, as was determined in early 2020 when Paramount conducted a strategic review of its assets. Simon & Schuster is a highly valuable business with a recent record of strong performance; however, it is not video-based and therefore does not fit strategically within Paramount's broader portfolio."

05:38 EST Amazon Web Services launches infrastructure region in India - Amazon Web Services, or AWS, an Amazon.com company, announced the launch of its second AWS infrastructure Region in India-the AWS Asia Pacific Region. Starting immediately, developers, startups, entrepreneurs, and enterprises, as well as government, education, and nonprofit organizations, will have greater choice for running their applications and serving end users from data centers located in India. Customers will have access to advanced AWS technologies to drive innovation including data analytics, security, machine learning, and artificial intelligence.

05:25 EST AllianceBernstein, Societe Generale to form cash equities JV - AllianceBernstein (AB) and Societe Generale (SCGLY) announced their plans to form a joint venture, or JV, combining their cash equities and equity research businesses. For both Bernstein Research's and Societe Generale's clients, this new joint venture would offer a suite of services across cash equities and research, combined with Societe Generale's integrated equity capital markets, equity derivatives and prime services platforms. The joint venture would provide investment insights into the American, European and Asia Pacific equity markets, in addition to unparalleled liquidity access and leading global trading technology. The merged entities would bring complementary strengths and a shared vision of a full-service equity brokerage business to support the needs of global investor and issuer clients. Societe Generale intends to take a 51% interest in the joint venture, with an option to reach 100% ownership after five years. The business would be run as a long-term partnership under the Bernstein name, headquartered in London. Upon closing, Robert van Brugge, CEO of Bernstein Research, would become CEO of the new entity for an initial term of five years, and Stephane Loiseau, Head of Societe Generale's cash equities business, would become deputy CEO. The proposed transaction has received the support of Societe Generale's and AllianceBernstein's boards. The closing is expected to occur before the end of 2023. The transaction is subject to workers council consultation, approval of regulators, and customary closing conditions. An equalization payment from Societe Generale to AllianceBernstein would occur at the close of the transaction. As AllianceBernstein will own less than 50% of the joint venture, AllianceBernstein anticipates deconsolidating Bernstein Research from its financial statements following the close of the transaction. The deconsolidation is expected to have a modestly positive impact on AllianceBernstein's operating margin. The planned joint venture is not expected to have an impact on AllianceBernstein's asset management business or Bernstein Private Wealth Management's business.